Definitive Healthcare Corp. (NASDAQ:DH) Receives $9.94 Consensus PT from Brokerages

Shares of Definitive Healthcare Corp. (NASDAQ:DH) have earned a consensus recommendation of “Hold” from the eleven research firms that are covering the company, MarketBeat.com reports. Nine research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $9.94.

Several research analysts recently weighed in on DH shares. Morgan Stanley cut shares of Definitive Healthcare from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $11.50 to $9.00 in a research report on Wednesday, May 8th. Barclays cut their target price on shares of Definitive Healthcare from $11.00 to $7.00 and set an “equal weight” rating for the company in a research report on Thursday, May 9th. Stifel Nicolaus lowered their price target on Definitive Healthcare from $11.00 to $9.50 and set a “buy” rating on the stock in a research report on Wednesday, May 8th. Needham & Company LLC reiterated a “hold” rating on shares of Definitive Healthcare in a research report on Wednesday, May 8th. Finally, Canaccord Genuity Group decreased their price objective on Definitive Healthcare from $10.00 to $8.00 and set a “hold” rating on the stock in a report on Wednesday, May 8th.

Definitive Healthcare Stock Performance

DH opened at $5.66 on Friday. The company has a market cap of $667.48 million, a price-to-earnings ratio of -3.23, a PEG ratio of 4.89 and a beta of 1.41. The company’s fifty day moving average price is $7.09 and its two-hundred day moving average price is $8.24. Definitive Healthcare has a 1-year low of $4.38 and a 1-year high of $12.45. The company has a current ratio of 2.30, a quick ratio of 2.30 and a debt-to-equity ratio of 0.20.

Definitive Healthcare (NASDAQ:DH) last announced its earnings results on Wednesday, February 28th. The company reported ($0.01) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.02). Definitive Healthcare had a positive return on equity of 0.51% and a negative net margin of 78.16%. The business had revenue of $65.93 million during the quarter, compared to analysts’ expectations of $66.01 million. On average, analysts expect that Definitive Healthcare will post 0.1 EPS for the current fiscal year.

Hedge Funds Weigh In On Definitive Healthcare

Hedge funds and other institutional investors have recently made changes to their positions in the company. Tower Research Capital LLC TRC boosted its position in Definitive Healthcare by 599.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,786 shares of the company’s stock valued at $58,000 after purchasing an additional 4,959 shares in the last quarter. Norden Group LLC purchased a new stake in shares of Definitive Healthcare during the first quarter valued at about $83,000. Berry Wealth Group LP purchased a new position in shares of Definitive Healthcare in the 1st quarter worth approximately $99,000. SG Americas Securities LLC bought a new position in shares of Definitive Healthcare during the 3rd quarter worth approximately $116,000. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in Definitive Healthcare during the first quarter valued at approximately $120,000. Institutional investors own 98.67% of the company’s stock.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.